These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23644503)

  • 1. Participants' perspectives on safety monitoring in clinical trials.
    Flynn KE; Kramer JM; Dombeck CB; Weinfurt KP
    Clin Trials; 2013 Aug; 10(4):552-9. PubMed ID: 23644503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motivators and barriers influencing willingness to participate in candidate HCV vaccine trials: perspectives of people who inject drugs.
    Park JN; White B; Bates A; Enriquez J; Liao L; Maher L
    Drug Alcohol Depend; 2012 Jun; 123(1-3):35-40. PubMed ID: 22071117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks and benefits of trial participation: A qualitative study of participants' perspectives in Russia.
    Zvonareva O; Kutishenko N; Kulikov E; Martsevich S
    Clin Trials; 2015 Dec; 12(6):646-53. PubMed ID: 26062594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The origin of informed consent].
    Mallardi V
    Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials.
    Brosteanu O; Houben P; Ihrig K; Ohmann C; Paulus U; Pfistner B; Schwarz G; Strenge-Hesse A; Zettelmeyer U
    Clin Trials; 2009 Dec; 6(6):585-96. PubMed ID: 19897532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hazard, risk and harm in clinical trials].
    Czarkowski M
    Pol Merkur Lekarski; 2008 Aug; 25(146):105-9. PubMed ID: 18942326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret.
    Stryker JE; Wray RJ; Emmons KM; Winer E; Demetri G
    Patient Educ Couns; 2006 Oct; 63(1-2):104-9. PubMed ID: 16242898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cultural feasibility studies in preparation for clinical trials to reduce maternal-infant HIV transmission in Haiti.
    Coreil J; Losikoff P; Pincu R; Mayard G; Ruff AJ; Hausler HP; Desormeau J; Davis H; Boulos R; Halsey NA
    AIDS Educ Prev; 1998 Feb; 10(1):46-62. PubMed ID: 9505098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Before the storm: informing and involving stakeholder groups in workplace biomarker monitoring.
    Musham C; Trettin L; Jablonski R
    J Public Health Policy; 1999; 20(3):319-34. PubMed ID: 10874405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Data and safety monitoring policy for National Institute of Allergy and Infectious Diseases clinical trials.
    Dixon DO; Weiss S; Cahill K; Fox L; Love J; McNamara J; Soto-Torres LE
    Clin Trials; 2011 Dec; 8(6):727-35. PubMed ID: 22024105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergency research: using exception from informed consent, evaluation of community consultations.
    Govindarajan P; Dickert NW; Meeker M; De Souza N; Harney D; Hemphill CJ; Pentz R
    Acad Emerg Med; 2013 Jan; 20(1):98-103. PubMed ID: 23570483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study evaluating an intervention designed to raise awareness of clinical trials among potential participants in the developing world.
    Dhai A; Etheredge H; Cleaton-Jones P
    J Med Ethics; 2010 Apr; 36(4):238-42. PubMed ID: 20338937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innovating information-delivery for potential clinical trials participants. What do patients want from multi-media resources?
    Shneerson C; Windle R; Cox K
    Patient Educ Couns; 2013 Jan; 90(1):111-7. PubMed ID: 22819269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethical communication in clinical trials. Issues faced by data managers in obtaining informed consent.
    Loh WY; Butow PN; Brown RF; Boyle F
    Cancer; 2002 Dec; 95(11):2414-21. PubMed ID: 12436450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sponsors' and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trials.
    Perez R; Archdeacon P; Roach N; Goodwin R; Jarow J; Stuccio N; Forrest A
    Clin Trials; 2017 Jun; 14(3):225-233. PubMed ID: 28345368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. To report or not to report: Exploring healthy volunteers' rationales for disclosing adverse events in Phase I drug trials.
    McManus L; Fisher JA
    AJOB Empir Bioeth; 2018; 9(2):82-90. PubMed ID: 29693508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seeking serenity: living with HIV/AIDS in rural Western Canada.
    Groft JN; Robinson Vollman A
    Rural Remote Health; 2007; 7(2):677. PubMed ID: 17516839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.